
VIRX
Healthcare · Biotechnology · $388,699 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · -2.6% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | Time not confirmed | -0.17 | 0.00 | +100.0% |
| Aug 6, 2025 | Time not confirmed | -0.22 | 0.00 | +100.0% |
| May 30, 2025 | Time not confirmed | -0.21 | 0.00 | +100.0% |
| Mar 31, 2025 | Time not confirmed | -0.19 | -0.27 | -39.7% |
| Nov 13, 2024 | Before the open | -0.24 | -0.27 | -12.5% |
| Aug 12, 2024 | Before the open | -0.37 | -0.25 | +32.4% |
| May 9, 2024 | After the close | -0.35 | -0.23 | +34.3% |
| Mar 7, 2024 | After the close | -0.31 | -0.35 | -12.9% |
| Nov 9, 2023 | Before the open | -0.30 | -0.33 | -10.0% |
| Aug 14, 2023 | Before the open | -0.29 | -0.32 | -10.3% |
| May 8, 2023 | After the close | -0.31 | -0.32 | -3.2% |
| Mar 13, 2023 | After the close | -0.38 | -0.27 | +28.9% |
| Nov 10, 2022 | After the close | -0.30 |
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including…
| -0.47 |
| -56.7% |
| Aug 9, 2022 | Before the open | -0.30 | -0.28 | +6.7% |
| May 10, 2022 | After the close | -0.31 | -0.28 | +9.7% |
| Mar 16, 2022 | Before the open | -0.43 | -0.31 | +27.9% |
| Nov 10, 2021 | Before the open | -0.31 | -0.40 | -29.0% |
| Aug 12, 2021 | Before the open | -0.24 | -0.25 | -4.2% |
| May 12, 2021 | After the close | -0.21 | 0.35 | +266.7% |
| Feb 24, 2021 | Before the open | -0.96 | -0.73 | +24.0% |
| Nov 16, 2020 | After the close | -1.18 | -1.01 | +14.4% |
| Aug 11, 2020 | After the close | -1.94 | -2.10 | -8.2% |
| May 7, 2020 | After the close | -2.44 | -1.75 | +28.3% |
| Mar 10, 2020 | After the close | -2.58 | -1.75 | +32.2% |
| Nov 12, 2019 | After the close | -2.97 | -2.10 | +29.3% |
| Aug 7, 2019 | After the close | -3.47 | -3.15 | +9.2% |
| May 8, 2019 | After the close | -6.06 | -3.50 | +42.2% |
| Mar 7, 2019 | After the close | -7.40 | -5.60 | +24.3% |
| Nov 5, 2018 | After the close | -7.70 | -6.30 | +18.2% |
| Aug 7, 2018 | After the close | -8.40 | -7.00 | +16.7% |
| May 8, 2018 | After the close | -9.36 | -7.35 | +21.5% |
| Mar 8, 2018 | After the close | -9.97 | -7.35 | +26.3% |